ERES East Resources Acquisition Company

eResearchTechnology and Inveresk Sign Agreement to Deliver Integrated Cardiac Safety and Clinical Pharmacology Services Fifth Clinical Research Organization Enters into Digital Cardiac Safety Monitoring Services Agreement with eResearchTechnology PHILADELPHIA, April 7 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, today announced it has entered into an agreement with Inveresk, one of the world's largest clinical research organizations. This alliance, the fifth for eRT, enables testing of new drug candidates in conjunction with emerging international cardiac safety regulatory guidance and technical standards. Under the agreement, Inveresk will conduct clinical trials at its Phase I unit in Edinburgh, Scotland, while eRT will perform digital collection, measurement, interpretation, review and distribution of cardiac safety data through its EXPeRT workflow-enabled data handling technology. The eRT technology is the first solution designed explicitly to meet emerging international guidance and standards related to cardiac safety monitoring services. "Inveresk's long operating history of providing comprehensive Phase I unit services for over fifteen years presented a great opportunity for eRT to extend its Thorough Phase I ECG Study partnership program to Europe," said Robert Brown, senior vice president of outsourcing partnerships for eRT. "The partnershipwill help to meet increasing demand from European and North American drug development organizations for the ability to conduct Thorough Phase I ECG studies in Europe. We are pleased to be announcing the Inveresk alliance and look forward to working closely with the Inveresk team to ensure effective execution of Thorough Phase I ECG studies." Based in Philadelphia, Pa., eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden Communications, +1-858-456-4533, for eResearchTechnology Web site: http://www.ert.com/

Copyright